Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor.

Lew W, Chen X, Kim CU.

Curr Med Chem. 2000 Jun;7(6):663-72. Review.

PMID:
10702632
2.

Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

Nguyen HT, Fry AM, Gubareva LV.

Antivir Ther. 2012;17(1 Pt B):159-73. doi: 10.3851/IMP2067. Epub 2012 Feb 3. Review.

PMID:
22311680
3.

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.

Ikematsu H, Kawai N.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Review.

PMID:
21973296
4.

Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling.

Jonges M, Liu WM, van der Vries E, Jacobi R, Pronk I, Boog C, Koopmans M, Meijer A, Soethout E.

J Clin Microbiol. 2010 Mar;48(3):928-40. doi: 10.1128/JCM.02045-09. Epub 2010 Jan 20.

5.

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG.

JAMA. 2000 Feb 23;283(8):1016-24.

PMID:
10697061
6.

Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

Feng E, Ye D, Li J, Zhang D, Wang J, Zhao F, Hilgenfeld R, Zheng M, Jiang H, Liu H.

ChemMedChem. 2012 Sep;7(9):1527-36. doi: 10.1002/cmdc.201200155. Epub 2012 Jul 16. Review.

PMID:
22807317
7.

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P.

Lancet. 2000 May 27;355(9218):1845-50. Erratum in: Lancet 2000 Nov 25;356(9244):1856.

PMID:
10866439
8.

Fitness of neuraminidase inhibitor-resistant influenza A viruses.

Baranovich T, Webster RG, Govorkova EA.

Curr Opin Virol. 2011 Dec;1(6):574-81. doi: 10.1016/j.coviro.2011.08.006. Epub 2011 Oct 1. Review.

9.

Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor.

Nishikawa T, Shimizu K, Tanaka T, Kuroda K, Takayama T, Yamamoto T, Hanada N, Hamada Y.

PLoS One. 2012;7(9):e45371. doi: 10.1371/journal.pone.0045371. Epub 2012 Sep 18.

10.

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.

Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group..

Clin Infect Dis. 2010 Nov 15;51(10):1167-75. doi: 10.1086/656802. Epub 2010 Oct 11.

PMID:
20936975
11.

Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients.

Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS.

J Infect Dis. 2013 Feb 15;207(4):553-63. doi: 10.1093/infdis/jis726. Epub 2012 Nov 29. Review.

12.

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.

Sugaya N, Ohashi Y.

Antimicrob Agents Chemother. 2010 Jun;54(6):2575-82. doi: 10.1128/AAC.01755-09. Epub 2010 Apr 5.

13.

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.

Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE.

JAMA. 1999 Oct 6;282(13):1240-6.

PMID:
10517426
14.

A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.

Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T.

Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):51-6. doi: 10.1016/j.bbrc.2012.10.095. Epub 2012 Nov 3.

PMID:
23131559
15.

Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV.

Viruses. 2010 Oct;2(10):2269-89. doi: 10.3390/v2102269. Epub 2010 Oct 13. Erratum in: Viruses. 2011 Aug;3(8):1415-6.

16.
17.

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14.

18.

Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.

Duan S, Boltz DA, Li J, Oshansky CM, Marjuki H, Barman S, Webby RJ, Webster RG, Govorkova EA.

Antimicrob Agents Chemother. 2011 Oct;55(10):4718-27. doi: 10.1128/AAC.00316-11. Epub 2011 Jul 5.

19.

A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase.

Hayakawa M, Toda N, Carrillo N, Thornburg NJ, Crowe JE Jr, Barbas CF 3rd.

Chembiochem. 2012 Oct 15;13(15):2191-5. doi: 10.1002/cbic.201200439. Epub 2012 Sep 10.

20.

Neuraminidase inhibitor resistance in influenza viruses.

Reece PA.

J Med Virol. 2007 Oct;79(10):1577-86. Review.

PMID:
17705169

Supplemental Content

Support Center